- Home
- RPTX vs PEPG Comparison
RPTX vs PEPG Comparison
Compare RPTX & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- PEPG
- Stock Information
- Founded
- RPTX 2016
- PEPG 2018
- Country
- RPTX Canada
- PEPG United States
- Employees
- RPTX N/A
- PEPG N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- RPTX Health Care
- PEPG Health Care
- Exchange
- RPTX Nasdaq
- PEPG Nasdaq
- Market Cap
- RPTX 63.9M
- PEPG 52.4M
- IPO Year
- RPTX 2020
- PEPG 2022
- Fundamental
- Price
- RPTX $1.41
- PEPG $1.40
- Analyst Decision
- RPTX Strong Buy
- PEPG Buy
- Analyst Count
- RPTX 3
- PEPG 3
- Target Price
- RPTX $4.50
- PEPG $7.67
- AVG Volume (30 Days)
- RPTX 94.4K
- PEPG 169.8K
- Earning Date
- RPTX 08-05-2025
- PEPG 08-07-2025
- Dividend Yield
- RPTX N/A
- PEPG N/A
- EPS Growth
- RPTX N/A
- PEPG N/A
- EPS
- RPTX N/A
- PEPG N/A
- Revenue
- RPTX $1,073,000.00
- PEPG N/A
- Revenue This Year
- RPTX N/A
- PEPG N/A
- Revenue Next Year
- RPTX N/A
- PEPG N/A
- P/E Ratio
- RPTX N/A
- PEPG N/A
- Revenue Growth
- RPTX N/A
- PEPG N/A
- 52 Week Low
- RPTX $0.89
- PEPG $0.88
- 52 Week High
- RPTX $4.29
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- RPTX 51.83
- PEPG 48.28
- Support Level
- RPTX $1.33
- PEPG $1.37
- Resistance Level
- RPTX $1.48
- PEPG $1.49
- Average True Range (ATR)
- RPTX 0.05
- PEPG 0.09
- MACD
- RPTX -0.01
- PEPG -0.00
- Stochastic Oscillator
- RPTX 34.37
- PEPG 38.46
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.